Loading peptide directory…
Side-by-side
Pick up to 3 peptides and see their key facts side by side. Useful for narrowing a search before deciding which page to read in full.
1 of 3 selected.
| Field | Last updated |
|---|---|
| Aliases | Proxofim, FOXO4 D-retro inverso peptide, FOXO4-p53 interaction antagonist |
| Category | Longevity |
| Formula | — |
| Molecular weight | 3260.7 Da |
| Half-life | hours (preclinical) |
| Mechanism (summary) | FOXO4-DRI is a designed D-retro-inverso peptide built from the FOXO4 interaction surface and engineered to disrupt the FOXO4–p53 axis specifically in senescent cells. It is a research-stage senolytic with no human clinical trials in the retrieved literature. |
| Dosing notes | Dosing is model-dependent in preclinical work. Accessible abstracts do not provide a reliable standardized dose table for cross-study comparison. Human dose, route, and frequency are unspecified because no human trial evidence was retrieved. |
| Storage |
Peer-reviewed stability data were not identified. Standard synthetic-peptide supplier guidance would favor lyophilized cold storage and freeze-thaw minimization; that remains generic peptide handling guidance, not FOXO4-DRI-specific validated stability data. |
| Read more | Full reference → |
|---|